jturano7423

Investing in Autism Treatment

Sept.19**Isn't it ironic after Cramer touts NSTK on his Video at the end of July that he 'urges investors to buy NSTK' because of RNAI potential and just yesterday, Michael Shulman of 'Biotech Blitz' discusses the over Hype and tremendous costs regarding RNAI. And for small companies it's at least a decade away from any approvals. So much for RNAI and NSTK!

Investing in Autism Treatment

September 14, 2007
After several inquires written to seekingalpha re:that the last piece of news posted on 'Nstk' was on April 6, 2007, seekingalpha removed the dates on the site. "BRILLIANT"
Instead of updating the site someone decided just to remove the dates. That doesn't fix the problem. If this is a communication site for investors then there is an injustice being served!
EVEN JIM CRAMER HAS TOUTED THIS STOCK A TOTAL OF 30 TIMES SINCE MARCH 16TH UP UNTIL LAST FRIDAY, SEPT.7TH, SO ISN'T THAT NEWSWORTHY?
THIS MUST BE THE BEST STOCK TO INVEST IN FOR THE NEXT DECADE ACCORDING TO HIM.
Why don't one of your biotech editors research this information and report on it. All is fair isn't it?
The new site looks great but the interior needs
updating too.
JIMMY T.

Investing in Autism Treatment

September 13th,
In today's fast world of communications it seems
as if 'SEEKINGALPHA' has either disregarded my post on Sept.2nd, or misplaced it. I find it hard to believe that the last article posted regarding 'nstk' was last April 2007?
This is a stock Touted by Jim Cramer a total of 30 Times to date since March 2007.
You mean to tell me that no news regarding Autism, Obesity, Diabetes, Osteoporosis, and RNAI, the areas that is the leading forefront of NSTK has made any news at all for the company.
Electronic communication should be faster than a carrier pigeon, right MICK?

Genzyme's Controversial Buyback was Predictable

Derek Lowe this was an excellent article. Quite informative.
Since you did your homework on this article and investigated
so well on it, I was wondering if an author of your stature would undertake what I feel is mere over-hype on a specific biotech company.the company is NASTECH PHARMACEUTICAL (NSTK).
It has been stated repeatedly that in the areas of Autism, Osteoporosis, Diabetes, Obesity and RNAI that nstk will be successful. I believe that this is so far from the truth and probability, that it warrants your expert opinion on the subject.
Please when you can, it would be gratefully appreciated!
JIMMY T.

Is Biotech on the Verge of a Breakout?

September 10th,
Brett scott you maybe on the money with this report.
If you select companies that have good revenue, sales growing quarterly, little or no debt, a return to equity increasing yearly,
potential new products not in the very early stages, and a management team that is effective, then investors can pick and choose the ripe fruits off the tree with careful due diligence.
Otherwise investors could be walking through a large parcel of Land Mines. Some tree's are rotten, some are dwarfs and some need another decade to grow. Potential is one thing but Time, Money, and approvals are large hurdles for some companies to
jump over, and these are the ones that should be left behind!
One level of measure is where has the stock price gone from 5 years ago until now! Has researchers over targeted the company's
stock price year after year and missed their goal?
It may be time but caution should be considered when selecting Biotech's.
JIMMY T

Jim Cramer's Mad Money Lightning Round Picks, 8/16/07

September 1, 2007
The Feuerstein's mailbag article should extinguish the level of flames of hope in RNAI for NSTK and the other three areas touted by Mr.Cramer

Investing in Autism Treatment

SEPTEMBER 2, 2007
UPDATE-NSTK
FEUERSTEIN'S MAILBAG!
LAST ARTICLE POSTED BY SEEKINGALPHA WAS APRIL 6TH ?

Jim Cramer's Mad Money Lightning Round Picks, 8/16/07

SEPTEMBER 2, 2007
UPDATE-NSTK
FEUERSTEINS'S MAILBAG-A MUST READ!
Last article posted by seekingalpha was last April?

Authentidate Holding: Coghill Capital Discloses 9.9% Stake, Pursues Changes

August 30th, 2007
Good article Mr. Juricic. From my 29 years of experience as an investor, I believe stronly that ADAT will become the Fairy Tale Story to come real soon. At current momentum, new contracts,
little bleeps every 10-15 days of uptick volume is signaling future high volume days coming. Once
the volume starts above 200,000 consistantly and trending higher that is the exact moment to jump aboard. In my opinion, this can be a $8 dollar stock by spring 2008!
jt7423

Expecting a Strong Move in Arena Pharma

Dan Pritch
Good article, thank you.
Maybe in the near future you may want to consider giving your prospective on 'NSTK'. I find and feel this is a story in a half.
It has all the ingredients of something to really write about.
Tremendous Hype, Chronic insider selling, Poor Sales, 10 year minus return on equity, Over played opportunities in the areas of Autism, Obesity, Diabetes, and RNAI. Lastly and truly, years away from potential FDA approvals with all their testing phases and hurdles they must jump perfectly to win approvals. One of the most overpriced Biotech's stocks in the market today in my opinion. Please consider Nstk as a future story of your personal perspective.
Thank you,
jt7423

Welcome to the New Seeking Alpha

Mick Weinstein.
Fantastic New Look!
Please continue your articles regarding BIOTECH, they are so
informative and resourceful to me and I'm sure to other readers too.
Best of all your authors are writing precise data and unbiased opinions giving the shareholders and investors the most realistic
viewpoints.
Best of Luck!
Most Appreciated!
jturano7423

Profiting from the Cyclical Nature of Biotech Stocks

Your article is right on. Although the market has been in a tizzy of late and there are many unknown probabilities,
potential recession, and so forth you assessment happens to be accurate. Having said that, in following biotech stocks, one in particular does tend to rise during sept.,oct.,and november, that's nastech pharmaceutical.
However, just as it always seems to go up during this time frame, it always seems to go down systematically
in December, january, and february like clock work! Of course the smart ones know to get out before the year end
earnings report surfaces! Thank you Dan for an informative report, keep up the good work!
IFF

Happy To Have Sold 'Value Trap' Amgen

Dear Mike Goodson, I commend you for stating what you did and to make a new stance although you loved the stock. It's not easy when you own a company like amgn and feel your in the right stock with all its potential
besides. As you said it was a value trap and just looking at that 5 year chart I can fully understand.
Which brings me to 'nstk' with a similar chart for 5 years(about the same value consistently), except this is not a stock of the same level. But when recent statements that nastech has potential in three areas being, Autism, Obesity, and Rnai, it raised a red flag to me. I found other companies way ahead of 'nstk' in all three areas, so
maybe it's more Hype than reality. There ahead by years and later phases too. nstk is in the early stages so they are probably 5-15 years away, which makes me wonder as a shareholder that maybe this is a 'Value Trap' too.
What's your perspective Mike,
Jimmy T

Jim Cramer's Mad Money Lightning Round Picks, 8/16/07

EXPERT ON 'NSTK' What make someone an expert on nstk? Research? Knowledge?
I disagree with jim Cramer that 'nstk' is a stock to be in, especially in 2007. In looking at the three areas mentioned by Mr.cramer, obesity,autism, and Rnai I believe nstk is far behind in those areas and believe they will have great difficulties advancing in those areas too.*****In the Pipeline: Diabetes and Obesity Archives
Several companies have been working on PPAR alpha drugs for a long time now, and ... Novartis is the company in the lead, with a compound well into ...
corante.com/pipeline/a... - 23k - Cached
OBESITY DRUG NEARS APPROVAL*
www.drugtopics.com/dru...

AUTISM
Dr. Joseph Buxbaum heads up the Autism Genome Project at the Mount Sinai School of Medicine. 
www.msnbc.msn.com/id/7...
‘I think within ten years we'll have found the genes of major affect and most of the genes of minor affect. That will then lead to reasonable targets for drug interventions.’
— DR. JOSEPH BUXBAUM
Mount Sinai School of Medicine
Once genes are identified, there will be targets for drug intervention.
Jansen Pharmaceutica recently applied to the Food and Drug Administration for approval of its antipsychotic drug Risperdal for patients with autism.  It's the first time in history a pharmaceutical company has targeted autism as a disease.
“There are over a million and a half people with autism,” said Shestack. “And they have it from age 2 to age 70. And there is a tremendous opportunity for a company that wants to do well by doing good.”
**** 
What medications are available?
www.biotechwatch.com/k...
The most complex of all diseases and the most difficult to treat and get approval

Regarding: RNAI
Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations with RNAi Therapeutics for CNS Diseases
biz.yahoo.com/bw/07073...

“Drug & Market Development Publications”
THE LEADING PROVIDER OF QUALITY LIFE SCIENCE MARKET ANALYSIS,OPPORTUNITY ASSESMENT, AND TACTICAL GUIDANCE
RNAi is the hottest topic in biotechnology and is positioned to revolutionize research and drug discovery.
Companies Profiled
Acuity Pharmaceuticals
AGY Therapeutics
Alnylam Pharmaceuticals
AntiSense Therapeutics
Benitec Australia
CytRx
Centa
Hemispherx Biopharma
International Therapeutics
Intragigm
ISIS Pharmaceuticals
Noxxon Pharma AG
Nucleonics
Sima Therapeutics
Alugen AG
Cenix BioScience
Compugen
Galapagos Genomics
Immusol
Ingenium Pharmaceuticals
Lexicon Genetics
Phenomix
Phylonix Pharmaceuticals
Zyogen
Amaxa
Ambion
CombiMatrix
Cyclacel
Cynellect
Dharmacon
Eurogentec
ExpressOn BioSystems
Gene Therapy Systems
Imgenex
Invitrogen
Mirus Bio
Ocimum Biosolutions
Plus more!
*LOOK AT THE COMPETITORS AND NOTICE ‘NSTK’ DIDN’T MAKE THE LIST**

POINT**I DO NOT MIND GETTING INFO THAT A STOCK MAYBE DEEMED NECESSARY TO INVEST IN.
IF THE INFORMATION THAT IS PROVIDED TO SHAREHOLDERS WEIGH IN THEIR FAVOR, THEN
FURTHER DD HOMEWORK IS WARRANTED FOR INVESTMENT CONSIDERATIONS.
HOWEVER, WHEN INFORMATION REGARDING A SPECIFIC COMPANY SEEMS TO GOOD TO BE TRUE, AND RESEARCH PROVES JUST THAT, THEN USING ONES AUTHORITY,CREDITABILTY...
TO PUT FORTH SUCH INACCURRACIES WHETHER BY MISTAKE OR FOR OTHER REASONS OF WHICH ARE INEXPLAINABLE, THEN ONE HAS TO WONDER WHY THIS WAS DONE IN SUCH A MATTER OF PURE HYPE! THERE LIES THE PROBLEM TO ALL SHAREHOLDERS!
IN CONCLUSION, IF THE THREE AREAS OF OBESITY, AUTISM, AND RNAI WAS PLAYED UP IN AN
EXAGERATING MANNER, THEN WHO BENEFITED THE MOST FOR THE RECOMMENDATION OF INVESTING ‘NOW’ IN 2007, IN NASTECH PHARMACEUTICAL?
Jimmy T

Fishy Executive Compensation at Northfield Labs

Excellent report by 10q detective. It is refreshing to see someone stand up for the little guy instead of going with misinformed Hype and those who specifically tout a company no matter how well known they are.
Which leads me to Nastech Pharmaceutical, the injustice has been smeared all over the press and t.v. shows about how in the areas of autism,obesity, and rnai that this company has unlimited chances of success. This company
has been over Hyped to lead the little guy thinking that this company is the next eli lilly! Their chances in these areas are extremely remote for absolute success and I do not understand where certain individuals are going with this. What is the real motive? Please Mr.Detective, if anyone can get to the bottom of this it's you. It would be appreciated. This would be the story of the decade when you really find out and Nastech is not what it's portrayed to be!
JT